Protagenic Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025
Selling, General & Admin	3.62	3.52	1.19
Research & Development	0.69	0.98	0.38
Operating Expenses	4.26	4.5	2.59
Operating Income	-4.26	-4.5	-2.59
Interest Expense	-1.26	-1.5	-1.04
Currency Exchange Gain (Loss)	0.01	0.01	0.04
Other Non Operating Income (Expenses)	3.64	1.16	-
EBT Excluding Unusual Items	-1.85	-4.82	-3.59
Gain (Loss) on Sale of Assets	7.31	7.31	-
Other Unusual Items	0.02	-1.12	-
Pretax Income	5.46	1.37	-3.59
Net Income	5.46	1.37	-3.59
Net Income to Common	5.46	1.37	-3.59
Net Income Growth	-	-	-
Shares Outstanding (Basic)	2	2	5
Shares Outstanding (Diluted)	2	2	5
Shares Change	-62.49%	-56.65%	-
EPS (Basic)	2.94	0.59	-0.67
EPS (Diluted)	2.94	0.59	-0.67
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025
Free Cash Flow	-2	-2.81	-1.77
Free Cash Flow Per Share	-1.08	-1.21	-0.33
EBITDA	-4.21	-4.45	-
D&A For EBITDA	0.04	0.05	-
EBIT	-4.26	-4.5	-2.59